Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content

Disable motion

Cabozantinib Development Program

Cabozantinib is a tyrosine kinase inhibitor (TKI) discovered and developed by Exelixis.
Cabozantinib was shown in vitro to inhibit multiple receptor tyrosine kinases (RTK) including VEGFR, MET, and the TAM kinases (TYRO3, AXL, and MER). These receptors are involved in normal and pathologic processes such as tumor angiogenesis, invasiveness, metastasis, and immunomodulation of the tumor microenvironment.
This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.